Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 9039 results

  1. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Woundexpress MT602 (MIB261)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [TSID12421]

    Awaiting development Reference number: GID-TA12472 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ruxuplam for treating Huntington's disease [TSID12429]

    Awaiting development Reference number: GID-TA12476 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lotilaner for treating moderate to severe demodex blepharitis [TSID12419]

    Awaiting development Reference number: GID-TA12470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Satralizumab for treating relapsing myelin oligodendrocyte glycoprotein antibody associated disease [TSID12420]

    Awaiting development Reference number: GID-TA12471 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Kodex EPD system MT575 (MIB260)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

    Technology appraisal guidance
    Awaiting development

  12. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Pulsed Field Ablation for Atrial Fibrillation

    Awaiting development Reference number: GID-HTG10866 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Epilepsies in children, young people and adults (SeLECTS)

    In development Reference number: GID-NG10453 Expected publication date:  05 August 2026

    NICE guideline
    In development

  15. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development